TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 27, 2018

Primary Completion Date

June 28, 2022

Study Completion Date

July 15, 2022

Conditions
SafetyTolerabilityFeasibilityTreatment Efficacy
Interventions
DRUG

MDG1011

PRAME-T-Cell Receptor Gene Modified Autologous T Cells

OTHER

Investigator Choice therapy

Any intervention/therapy chosen by the investigator

Trial Locations (9)

Unknown

University Hospital Dresden, Dresden

University Hospital Erlangen, Erlangen

University Hospital Frankfurt, Frankfurt

University Hospital Freiburg, Freiburg im Breisgau

University Hospital Heidelberg, Heidelberg

University Hospital Leipzig, Leipzig

University Hospital Mainz, Mainz

University Hospital Regensburg, Regensburg

University Hospital Wuerzburg, Würzburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Medigene AG

INDUSTRY